What is the common examiner trap about Health & Education in UPSC exams?

They may ask which vaccine showed efficacy against 'pulmonary TB' only, when the key finding is against 'extrapulmonary TB'. Another trap is swapping the developer (e.g., 'Bharat Biotech developed VPM1002' when it was developed by SIIPL/Serum Institute).

What should UPSC aspirants remember about Health & Education for Prelims?

1. Target this Data: 50.4% efficacy of VPM1002 against extrapulmonary TB. 2. Target this Nodal Body: Indian Council of Medical Research (ICMR) conducted the PreVenTB trial. 3. Target this Legal Point: The policy precedent of early approval in 'clinical trial mode' as seen with Covaxin and TrueNat.

HealthGovernance

Take AI Challenge ▸

News 5 of 25

ICMR's PreVenTB Trial Shows VPM1002 Vaccine with 50.4% Efficacy Against Extrapulmonary TB, Targets Elimination by 2030

Q: Which apex biomedical research body conducted the PreVenTB trial mentioned in the article?

Indian Council of Medical Research, The article explicitly states that the PreVenTB trial was 'conducted by the Indian Council of Medical Research (ICMR)'. ICMR is India's apex body for biomedical research under the Department of Health Research.

Q: Consider the following statements regarding the PreVenTB trial findings: 1. The VPM1002 vaccine showed statistically significant efficacy against extrapulmonary tuberculosis (EPTB). 2. The trial primarily focused on evaluating vaccine efficacy in infants below the age of six years. 3. No other ongoing global TB vaccine trial has included extrapulmonary TB as an efficacy end-point. Which of the statements given above is/are correct?

Both 1 and 3, Statement 1 is correct: The article states '50.4% efficacy of VPM1002 against extrapulmonary TB (statistically significant)'. Statement 2 is incorrect: The trial involved individuals 'aged six years and above', not infants. Statement 3 is correct: The article notes 'none of the currently ongoing trials worldwide has included EPTB as the efficacy end-point'.

Q: According to the PreVenTB trial results published in the BMJ, what was the reported efficacy of the VPM1002 vaccine against all forms of tuberculosis (TB)?

21.4%, The article specifically mentions 'overall 21.4% efficacy of VPM1002 against all TB'. 50.4% is the efficacy against extrapulmonary TB only, and 64.6% is the efficacy in children aged 6-14 years against all TB.

Q: What is the primary public health argument made in the article for considering the deployment of vaccines like VPM1002?

To act as a pragmatic tool for immediate benefit while better options are developed., The core argument is against 'waiting for a perfect vaccine' and for 'deploying tools that reduce severe disease... can deliver immediate and tangible benefits'. It advocates for a pragmatic approach, citing precedents like Covaxin's early approval.

Health & Education Polity Science & TechHIGH

Target:UPSCMPSCTeachingSSC GAPrelims HighMains HighStatic GK Link

05 Jun 2026

~2 min

Source: The Hindu

Key Data:50.4% efficacy against EPTB64.6% efficacy in children 6-1421.4% overall efficacy12,700+ trial participants

Bodies:ICMRSIIPLCadila

Practice MCQs from today's news ▸

~2 min · Quick mode

What This Article Covers

1.ICMR's Phase III PreVenTB trial evaluated VPM1002 and Immuvac vaccines, showing 50.4% efficacy against extrapulmonary TB and over 60% efficacy in children.

2.The findings challenge the global search for a 'one-shot' vaccine, advocating for a holistic strategy combining detection, preventive therapy, and targeted vaccination.

3.For exams, focus on the trial's unique endpoint (EPTB), the institutions involved (ICMR, SIIPL, Cadila), and the policy precedent of early adoption seen with TrueNat and Covaxin.

The Big Picture

Prelims · HighMains · High

ICMR's landmark PreVenTB trial provides crucial data on new TB vaccines, showing significant efficacy against hard-to-diagnose extrapulmonary TB. This offers a pragmatic tool for India's ambitious TB elimination target, requiring a shift from waiting for a perfect vaccine to deploying layered public health strategies.

Exam Lens

Quick Exam Facts From News

Trial NamePreVenTB trial

Conducting BodyIndian Council of Medical Research (ICMR)

VPM1002 Efficacy (EPTB)50.4% (statistically significant)

VPM1002 Efficacy (Children 6-14)64.6% against all TB

Sample SizeMore than 12,700 household contacts

Trial Sites18 sites across India

1-Minute Revision

›Trial Name: PreVenTB trial
›Conducting Body: Indian Council of Medical Research (ICMR)
›Target this Data: 50.4% efficacy of VPM1002 against extrapulmonary TB.
›Target this Nodal Body: Indian Council of Medical Research (ICMR) conducted the PreVenTB trial.
›Target this Legal Point: The policy precedent of early approval in 'clinical trial mode' as seen with Covaxin and TrueNat.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

News Snapshot

💉

Vaccine Breakthrough

The PreVenTB trial is the first to evaluate and show significant vaccine efficacy against both pulmonary and extrapulmonary TB in individuals aged six and above.

🎯

Strategic Shift

The article argues for deploying moderately effective tools like VPM1002 now, rather than waiting indefinitely for a perfect 'silver bullet' vaccine.

⚖️

Policy Precedent

India's approach mirrors past decisions like approving TrueNat and Covaxin in 'clinical trial mode', emphasizing urgency and real-world deployment over perfect data.

Detailed Analysis & Strategic Depth

Context / Background

TB remains the world's deadliest infectious disease, with India bearing a disproportionately high burden. The global vaccine pipeline has been disappointing, primarily focusing on preventing pulmonary TB (PTB) and neglecting extrapulmonary TB (EPTB), which is harder to diagnose and more debilitating. India's National TB Elimination Programme aims for elimination (incidence <10 per 100,000) by 2025, a target requiring innovative tools.

Core Analysis & Implications

The PreVenTB trial data is a game-changer for three reasons. First, it provides the first efficacy signal against EPTB, addressing a hidden part of the epidemic. Second, the high efficacy in children (6-14 years) opens the door for a school-based booster strategy, filling a critical gap as India currently has no TB vaccination beyond infancy. Third, it demonstrates that a single-dose, BCG-based vaccine (VPM1002) can be logistically simpler and cost-effective for large-scale rollout in an LMIC like India.

Future Outlook / Way Forward

The authors propose a 'smarter TB strategy' integrating targeted vaccination of high-risk groups (household contacts, school children) with strengthened diagnostics, nutritional support (as low BMI reduced efficacy), and preventive therapy. This layered approach acknowledges that TB elimination requires a combination of tools, not a single breakthrough. Policy action must prioritize deploying available, evidence-backed solutions to gain immediate public health benefits.

Key Facts at a Glance

Trial NamePreVenTB trial

Conducting BodyIndian Council of Medical Research (ICMR)

VPM1002 Efficacy (EPTB)50.4% (statistically significant)

VPM1002 Efficacy (Children 6-14)64.6% against all TB

Sample SizeMore than 12,700 household contacts

Trial Sites18 sites across India

You've read the full analysis. Now test your understanding.

Practice exam-style questions based on this article.

Q1Static LinkageEasyUPSC, SSC, State PSC

Which apex biomedical research body conducted the PreVenTB trial mentioned in the article?

Q2Statement-basedHardUPSC

Consider the following statements regarding the PreVenTB trial findings:

1. The VPM1002 vaccine showed statistically significant efficacy against extrapulmonary tuberculosis (EPTB).

2. The trial primarily focused on evaluating vaccine efficacy in infants below the age of six years.

3. No other ongoing global TB vaccine trial has included extrapulmonary TB as an efficacy end-point.

Which of the statements given above is/are correct?

Q3Data-centricMediumUPSC, SSC

According to the PreVenTB trial results published in the BMJ, what was the reported efficacy of the VPM1002 vaccine against all forms of tuberculosis (TB)?

Q4Application/ImpactMediumUPSC, State PSC

What is the primary public health argument made in the article for considering the deployment of vaccines like VPM1002?

All 25 MCQs ▸

Read original article from The Hindu

You finished this topic

Practice 3 MCQs from this news Next Article

Explore Related Topics

Health & EducationView Topic MCQs →PolityView Topic MCQs →Science & TechView Topic MCQs →

PreviousPM Suryaghar Yojana and PM-KUSUM Achieve 13 GW Against 40 GW Target; Power Subsidies Hinder Adoption in Punjab, Tamil Nadu, Karnataka Next Urban Heat & Inequality Crisis: WHO Green Space Norm (9 sq.m./capita) vs. Chennai (0.81), Pune (1.4), Delhi (2.9)

Related Current Affairs

Health & Education Current Affairs

CDSCO Flags 17 Differences in Spurious Abhayrab Rabies Vaccine Batch KE25012

A raid in Delhi’s Mukherjee Nagar exposed a fake rabies vaccine racket selling spurious Abhayrab vials. CDSCO flagged 17 differences in the counterfeit batch, raising serious public health concerns given India’s high rabies death burden. The case underscores the need for stringent drug regulation and supply chain vigilance.

Social Issues Current Affairs

VP Launches India Valve Registry for Heart Valve Disease Research; TN Reports 2,590 Valve Replacements in 20 Months

The Vice-President launched the India Valve Registry, a first-of-its-kind clinician-led platform to collect real-world data on valvular heart disease and interventions in India. The registry will generate India-specific evidence to improve patient care, while Tamil Nadu's CMCHIS data reveals 2,590 valve replacements in 20 months, highlighting the burden of rheumatic heart disease and the success of state-led healthcare.

Science & Tech Current Affairs

National One Health Mission: ICMR Expands Waste-Water Surveillance to 75 Cities by 2027

The National One Health Mission is advancing with waste-water surveillance of 13 priority pathogens across 47 cities, set to expand to 75 cities by 2027. ICMR DG informs Rajya Sabha member about genomic hubs and integrated surveillance, while MHA drafts a National Biosecurity Policy. This is crucial for UPSC prelims (data points, schemes) and mains (health security, One Health approach).

Polity Current Affairs

SC Applies Section 498A to Live-in Relationships; NOTTO Launches Real-Time Organ Transplant Portal with Aadhaar Pledges

The Indian Express UPSC Key for August 4, 2026, covers multiple crucial topics: the Supreme Court's ruling extending Section 498A cruelty protection to live-in relationships, the launch of a real-time organ transplant portal by NOTTO, the Vikram Sarabhai Medal awarded to Annapurni Subramaniam, India's resilient fertiliser supply amid the Iran war, the science behind Europe's wildfires, and the Ceuta migrant crisis. These topics span Polity, Health, Science, Environment, and International Relations, offering direct material for UPSC Prelims and Mains.

Health & Education Current Affairs

IIT Kharagpur Applies for MD, IIT Madras Plans MBBS: IITs, IISc Redefine Medical Education

India's premier engineering institutes (IITs, IISc) are entering medical education, signaling a paradigm shift under NEP 2020. IIT Kharagpur applied for MD (March 2026), IIT Madras plans MBBS, and IISc's Tata Medical School will offer MD-PhD from 2027. This convergence aims to create 'physician-scientists' and reduce medical device imports, but faces regulatory and capital challenges.

Science & Tech Current Affairs

Proposed Patient Data Collective (PDC) Model for Rare Diseases in India Inspired by Amul Cooperative

A new proposal suggests creating a Patient Data Collective (PDC) for rare diseases in India, modeled on the Amul dairy cooperative. This collective would pool patient data to accelerate drug discovery and clinical trials, addressing the challenge of small patient populations for rare diseases.

Infrastructure Current Affairs

SCR Celebrates 60 Years: Kavach First Tested, DigiPay & Unmanned Crossing Elimination Achieved

South Central Railway (SCR) marks 60 years of transformation from Nizam-era narrow gauge to modern LHB trains and Kavach auto-protection system. Key milestones include first testing of India's indigenous train protection system (Kavach), elimination of all unmanned level crossings by 2018, and 100% LED-lit stations. With 93% electrification and 454 daily trains, SCR is a model zone for technological and safety upgrades.

Science & Tech Current Affairs

Stem Cell Therapy for Autism Restricted to Clinical Trials; Health Ministry Advisory Follows SC Order

The Union Health Ministry has reiterated that stem cell therapy for Autism Spectrum Disorder (ASD) can only be offered as part of approved clinical trials, not as routine or commercial treatment. This follows a landmark Supreme Court judgment in January 2026 that examined the issue. The advisory reinforces existing regulations under the Clinical Establishments Act, 2010, and the National Guidelines for Stem Cell Research, 2017.

Start Today's Quiz(25 Qs)

Take Today's Quiz

25 Qs • 5-7 Mins

ICMR's PreVenTB Trial Shows VPM1002 Vaccine with 50.4% Efficacy Against Extrapulmonary TB, Targets Elimination by 2030

Exam Lens

Quick Exam Facts From News

1-Minute Revision

News Snapshot

Vaccine Breakthrough

Strategic Shift

Policy Precedent

Detailed Analysis & Strategic Depth

Context / Background

Core Analysis & Implications

Future Outlook / Way Forward

Prelims Flashpoints

Key Facts at a Glance